Modality
ERT
MOA
CFTRmod
Target
IL-13
Pathway
Cell Cycle
MigraineCKD
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Aug 2030
Phase 1Current
NCT04814292
1,705 pts·Migraine
2018-02→2030-08·Completed
NCT05604526
1,196 pts·CKD
2017-02→2026-08·Terminated
2,901 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-205mo awayInterim· CKD
2030-08-224.4y awayInterim· Migraine
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Termina…
P1
Complet…
Catalysts
Interim
2026-08-20 · 5mo away
CKD
Interim
2030-08-22 · 4.4y away
Migraine
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04814292 | Phase 1 | Migraine | Completed | 1705 | eGFR |
| NCT05604526 | Phase 1 | CKD | Terminated | 1196 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 |